Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To evaluate the effect of androgen suppression therapy using leuprorelin focused on the bulbar function of patients with spinal and bulbar muscular atrophy

Next Previous
X
Search
Trial Profile

To evaluate the effect of androgen suppression therapy using leuprorelin focused on the bulbar function of patients with spinal and bulbar muscular atrophy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Sep 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Leuprorelin (Primary)
  • Indications X-linked bulbo-spinal atrophy
  • Focus Therapeutic Use

    • Most Recent Events

    • 02 Sep 2021 New trial record
    • 01 Sep 2021 Primary endpoint (the changes in the vallecular residue and pyriform sinus residue) has been met, as per results published in the Journal of Neurology .
    • 01 Sep 2021 Results published in the Journal of Neurology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top